Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Bevacizumab Stories

2013-09-16 12:28:09

Company invites individual and institutional investors to log-on to view presentation NEW YORK, Sept. 16, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that their September 12th RetailInvestorConferences.com presentation is now available for on-demand viewing. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers. DelMar's lead drug, VAL-083, is being developed in the U.S. to treat glioblastoma...

2013-09-10 23:00:52

Leiter’s Compounding Pharmacy is voluntarily recalling three lots of its sterile products due to concerns of sterility assurance with Front Range Laboratories, Leiter's Compounding Pharmacy's independent testing laboratory. San Jose, Calif. (PRWEB) September 10, 2013 Leiter’s Compounding Pharmacy is voluntarily recalling three lots of its sterile products due to concerns of sterility assurance with Front Range Laboratories, Leiter's Compounding Pharmacy's independent...

2013-09-09 08:27:39

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference NEW YORK, Sept. 9, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that Jeffrey Bacha, B.Sc., MBA, president & CEO, will present at RetailInvestorConferences.com. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers. DelMar's lead drug, VAL-083, is being developed in the U.S. to treat...

2013-09-09 08:26:48

INCLINE VILLAGE, Nev., Sept. 9, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2013, of approximately $97 million, as compared with actual revenue of $85 million for the third quarter of 2012, an approximate 14 percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) The forecasted growth in revenues is driven by increased second quarter 2013 sales for Avastin(®),...

2013-09-03 08:27:46

DelMar Developing VAL-083 in U.S. and China to Treat Aggressive Cancers VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), developer of advanced cancer therapeutics, will be featured as a presenting company at the 15(th) Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Monday, September 9(th) at 3:15 p.m. EDT in Room 7.02 at the...

2013-08-28 08:27:13

Clinical Pathways Developed by Oncologists Tend to Focus on the More Advanced Stages of Cancer, According to a New Report from Decision Resources BURLINGTON, Mass., Aug. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that clinical pathways developed by physician groups are not preventing oncologists from prescribing their preferred therapies for advanced non-small-cell lung cancer...

2013-08-19 15:03:25

A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer. "There has been a great deal of debate...

2013-08-15 08:26:16

Eylea's Convenient Dosing Frequency Likely Drives Product Initiation, Although High Satisfaction Among Prescribers Likely Motivates Continued Use, According to a New Report from BioTrends Research Group EXTON, Penn., Aug. 15, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed retinal specialists/general ophthalmologists now treat 26 percent of their intravitreal...

2013-08-14 16:26:13

Randomized phase II trial will investigate vaccine therapy combined with Avastin for patients with recurrent glioblastoma multiforme CHICAGO, Aug 14, 2013 /PRNewswire-USNewswire/ -- Northwestern Medicine(®) recently joined a landmark clinical trial to investigate if a vaccine made from a patient's own brain tumor is effective in slowing tumor progression and extending survival. The randomized phase II trial will study how well giving the study vaccine with or without Avastin...

2013-08-14 08:27:06

Treatment Rates with Avastin in Endometrial Cancer are Low but Most Surveyed Oncologists Believe that Angiogenesis Inhibitors Can Play a Role in Treatment of Endometrial Cancer, According to a New Report from Decision Resources BURLINGTON, Mass., Aug. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Genentech/Chugai's Avastin, although currently not FDA-approved for...